GlobeNewsWire
01 Dec 2025, 14:00 UTC · 42w ago
Verdict
Headline takes no side. We score NTHI +0.90 across three claims — strongly bullish.
+0.90strongly bullish
More positive than 96% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Preclinical findings demonstrate that combining NEO100 with focused ultrasound enhances antitumor effects across multiple primary and metastatic brain tumor types.
So whatPositive efficacy data for a lead candidate in a high-unmet-need area (brain tumors) typically drives investor optimism and valuation for clinical-stage biotech.
More positive than 93% of claims this week
NeOnc intends to move NEO100 combined with focused ultrasound into future clinical trials.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 78% of claims this week
The company utilized an AI-driven, 3D-bioprinted New Approach Methodology (NAM) to identify NEO100 as a leading sonodynamic therapy agent.
More positive than 65% of claims this week
Which stocks this story touches
More positive than 96% of ticker scores this week
The company announced positive preclinical findings showing that ultrasound enhances the potency of its NEO100 therapeutic in treating brain tumors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
4h ago
−63.0%
Price is moving against the score
$3.31 vs $8.95 close before publication (Nov 28) · not market-adjusted
NTHI chart →
